Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc Call to Discuss Eye Care Collaboration with Abbvie Inc Transcript

Sep 13, 2021 / 12:00PM GMT
Release Date Price: $43.4 (+31.20%)
Operator

Good morning and welcome to the AbbVie and REGENXBIO announce eye care collaboration conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to Mr. Patrick Christmas, Chief Legal Officer of REGENXBIO. You may begin.

Patrick J. Christmas
REGENXBIO Inc. - Senior VP & Chief Legal Officer

Good morning and thank you for joining us today. Speaking on behalf of REGENXBIO this morning is Ken Mills, REGENXBIO's President and Chief Executive Officer; joined by Vit Vasista, our Chief Financial Officer; Dr. Steve Pakola, our Chief Medical Officer; Curran Simpson, our Chief Operations and Technology Officer; and Ram Palanki, our Senior Vice President of Commercial Strategy and Operations, who will each be available for questions and answers.

Earlier this morning, REGENXBIO issued a press release announcing an eye care collaboration with AbbVie. This press release is available on our website at www.regenxbio.com<

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot